Perceptive Advisors LLC Buys 2,255,252 Shares of Provention Bio Inc (NASDAQ:PRVB)

Share on StockTwits

Perceptive Advisors LLC grew its position in Provention Bio Inc (NASDAQ:PRVB) by 338.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,921,574 shares of the company’s stock after purchasing an additional 2,255,252 shares during the period. Provention Bio comprises approximately 0.9% of Perceptive Advisors LLC’s holdings, making the stock its 27th biggest holding. Perceptive Advisors LLC owned about 0.06% of Provention Bio worth $43,532,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of PRVB. Credit Suisse AG bought a new stake in Provention Bio during the fourth quarter worth about $1,844,000. Stifel Financial Corp bought a new stake in Provention Bio during the 3rd quarter worth about $512,000. Rice Hall James & Associates LLC acquired a new stake in Provention Bio in the 4th quarter valued at about $873,000. Laurion Capital Management LP increased its position in Provention Bio by 410.0% in the 4th quarter. Laurion Capital Management LP now owns 68,340 shares of the company’s stock valued at $1,018,000 after acquiring an additional 54,940 shares in the last quarter. Finally, California Public Employees Retirement System bought a new position in shares of Provention Bio in the fourth quarter worth about $679,000. Institutional investors own 18.45% of the company’s stock.

Provention Bio stock traded up $1.25 during trading hours on Thursday, reaching $8.40. 452,701 shares of the company’s stock traded hands, compared to its average volume of 611,455. Provention Bio Inc has a fifty-two week low of $2.20 and a fifty-two week high of $22.82. The firm has a market capitalization of $341.13 million, a price-to-earnings ratio of -7.85 and a beta of 5.62. The firm’s 50 day moving average is $11.66 and its 200-day moving average is $10.88.

Provention Bio (NASDAQ:PRVB) last issued its earnings results on Thursday, March 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. On average, analysts forecast that Provention Bio Inc will post -1.13 EPS for the current fiscal year.

In other Provention Bio news, insider Jason Hoitt acquired 4,500 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $28,125.00. Insiders own 19.60% of the company’s stock.

Several research firms have recently commented on PRVB. ValuEngine raised shares of Provention Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. HC Wainwright restated a “buy” rating on shares of Provention Bio in a research report on Wednesday, March 18th. Cantor Fitzgerald assumed coverage on Provention Bio in a report on Friday, January 24th. They set an “overweight” rating and a $25.00 price objective on the stock. Zacks Investment Research lowered Provention Bio from a “hold” rating to a “sell” rating in a research report on Thursday, March 19th. Finally, SVB Leerink reissued an “outperform” rating on shares of Provention Bio in a research note on Thursday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.45.

Provention Bio Company Profile

Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.

See Also: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding PRVB? Visit to get the latest 13F filings and insider trades for Provention Bio Inc (NASDAQ:PRVB).

Institutional Ownership by Quarter for Provention Bio (NASDAQ:PRVB)

Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with's FREE daily email newsletter.

Leave a Reply